GBA's "2021 Stock Phantasma"

In investing Van all you run into are followers. You can always tell a follower because they try to hang on to information that they have stolen from someone else (or borrowed) In the Hedge Fund world there are very few free thinkers and leaders and the few that are are instantly
" followed. " Copy cat has become faster copy cat. Yea I left a message for that other thread but it wasn't an apology. That's for sure.

I feel antsy.... Earnings season is coming I don't have a good feel--
 
On of the problems is I have not created my usual watch list. The watch list s the most valuable tool for an investor. In a way these threads become a watch list as often i go back into earlier pages for an idea and that's most likely what's going to have to happen this time. Do i not have a watch list because I failed to create one? Or was my inner mind not letting me? I think the latter.

I did find a piece of paper thrown towards the bathroom that has some names on it...When it was created I'm not sure but I think it's fairly recent--

The Names On It--

TER- We discussed that one. Robots. 5G and a stock I sold $30 too early. !!

CRM & SNAP<----- Here is where I am hovering.

ST- Sensata car sensors and stuff

ORBC- Orbcom i forget...

NEE- That's our wind and solar energy play Utility

BG- Soybeans?


I am most interested in two other names for now))))

AMTX-- Van did you watch that video presentation?

XPEV-- Van where does this have to fall to for you to be interested......
 
--- ORBC --- they track goods via satellite

Description
ORBCOMM Inc. provides Internet of Things solutions in the United States, South America, Japan, Europe, and internationally. The company offers network connectivity, devices, device management, and web reporting applications that are designed to track, monitor, control, and enhance security for various assets, such as trailers, trucks, rail cars, sea containers, power generators, fluid tanks, marine vessels, diesel or electric powered generators, oil and gas wells, pipeline monitoring equipment, irrigation control systems, and utility meters in transportation and supply chain, heavy equipment, fixed asset monitoring, and maritime industries, as well as for governments. It also provides satellite automatic identification service data services for vessel navigation and to enhance maritime safety for government and commercial customers; and vehicle fleet management, as well as in-cab and fleet vehicle solutions using various network platforms, including its own constellation of low-Earth orbit satellites
 
Sensata Technologies Holding plcST recently raised revenue guidance for fourth-quarter 2020 on better-than-expected order trends. Despite severe market conditions triggered by the coronavirus-induced adversities, the higher revenue expectations for the to-be-reported quarter exhibit the operating leverage of the company’s business model.

In concurrence with third-quarter results, Sensata had offered guidance for the fourth quarter that included adjusted earnings expectations in the band of 64-72 cents per share and adjusted net income of $100-$114 million. Although no business update was made available on these two metrics, management currently expects fourth-quarter revenues to lie within $902 million to $907 million, up from prior expectations of $810-$850 million. The improved revenue outlook is primarily driven by sustained business activities in Automotive and Industrial businesses which, in turn, translated into higher order schedules.

Catering to a wide range of customers from Tier 1 compressor suppliers to industrial manufacturers, Sensata shares a long-standing relationship with a geographically diverse base of multinational companies and leading original equipment manufacturers. It develops mission-critical sensor-rich solutions to address both current and evolving technological needs. Strong relationships combined with robust innovation capabilities serve as its key growth drivers. With these capabilities, the company is focused on establishing and optimizing a highly-efficient global manufacturing as well as supply chain network that has likely resulted in the healthy order flow.
 
ST has an interesting chart it didn't react too well to that guide upwards which as a warning sign it then took two distinct steps down.. I'd wait for one more step down but not too far away I like this name $1 below where we are.

ST-$ 54.70

Buy Zone-> $53.30
 
CRM has had a bad month! $230- $213.

Between $207 & $213 there is some support. But YTD this stk has DONE NOTHING!!!! I see this as a larger warning sign....
 
COLL

Collegium Pharmaceutical, Inc.
January 6, 2021
– Xtampza®ER Revenues Expected in the Range of $155.0 million to $165.0 million –

– Nucynta®Franchise Revenues Expected in the Range of $175.0 million to $185.0 million –

– Adjusted EBITDA Expected in the Range of $160.0 million to $170.0 million –

STOUGHTON, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) --Collegium Pharmaceutical, Inc.(Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced its 2021 full-year financial guidance.

“Collegium achieved a financially transformative year in 2020, driven by Xtampza ER growth and the acquisition of the Nucynta franchise. We delivered on our broad operational objectives and prioritized the health and safety of our people, customers and the communities that we serve,” said Joe Ciaffoni, President and Chief Executive Officer of Collegium. “As we head into 2021, we remain steadfast in our commitment to being the leader in responsible pain management, maximizing the potential of our differentiated pain portfolio and creating value for our shareholders.”

“Our 2021 revenue outlook is supported by Xtampza ER growth, stable profit contribution from the Nucynta franchise and a commitment to leverage our cost structure,” said Paul Brannelly, Executive Vice President and Chief Financial Officer of Collegium. “This year, we expect to generate significant cash flow from operations and will deploy our balance sheet in a disciplined manner that invests in the long-term growth of our company.”

Financial Guidance for 2021

  • Xtampza®ER revenues are expected in the range of $155.0 million to $165.0 million

  • Nucynta®franchise revenues are expected in the range of $175.0 million to $185.0 million

  • Adjusted EBITDA (excluding stock-based compensation) is expected in the range of $160.0 million to $170.0 million

  • Total operating expenses are expected in the range of $125.0 million to $135.0 million
 
NEE WAS $74 area when we gave it out on page 1 of this thread. It is now $82.
For a utility that's not nothing!

I think I see an opportunity again for Curevac. CVAC--

Moving Average Cross over alert** I think.

Good news---

BERLIN, Jan 17 (Reuters) - German pharmaceutical giant Bayer is examining whether it can help CureVac to produce its experimental COVID-19 vaccine, its chief executive was quoted as saying on Sunday.

Though inoculation campaigns have started around the world using various COVID-19 vaccines, many countries say their ability to get shots into arms is being limited by lower than expected supplies owing to a shortage of production.

"We are prepared to pull out all the stops for this," Werner Baumann told the Welt am Sonntag newspaper.

"This is not primarily about financial considerations but about making the vaccine available as quickly as possible."

Bayer agreed this month to help fellow German company CureVac with development of its COVID-19 vaccine candidate, which is in late-stage clinical trials and has not yet been approved.

Baumann said the drugmaker was "intensively examining" whether to expand its co-operation to include manufacturing the vaccine for CureVac.

"With our production network in Germany and the USA and the corresponding lead time, we would in principle be in a position to produce vaccine in larger quantities," he said.

On Friday U.S. drugmaker Pfizer said there would be a temporary slowdown of shipments of the vaccine it developed with German partner BioNTech, citing changes in manufacturing processes-- to boost output.


Ok so old people are dying from the Pfizer shot as well. Not good for 80 and 90 year olds...
Slow down in production this opens the door a bit for CVAC,

Chief Executive Fran-Werner Haas told Germany's Handelsblatt newspaper that the company expected to receive clearance for its covid-19 vaccine by the beginning of the second quarter.
 
<<<WATCH LIST>>>

AMTX-- Van did you watch that video presentation?

XPEV-- Van where does this have to fall to for you to be interested......

COLL--

CVAC--

ST--

SNAP--
 
Remember Aqua Bounty?

Interesting phone call with my brother-in-law the stock broker. There is $30K in some account that we can play with and what stock does he mention but the Salmon Farming story Aqua Bounty... There is a stock picking women who he follows (I don't know who she is) but everyone follows everyone as I was saying there are few leaders. She is a leader. She's been building a big position and I have to double check this but apparently Warren Buffett bought in???

A recent secondary is out of the way... @$6.50 My source here probably ran that so he may be prejudiced to favoring but he said a lot of smart money bought in. damn it where was I. The stk is Now $11!!!!

AQB-> $11. <---- Van where did we have this originally?
 
You must log in or register to reply here.
Back
Top